Great Company, Bad Stock  

Oleh:

Jacobs, Tom

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 23 no. 2 (Feb. 2005), page 173-174.
Topik: company; great company; bad stock

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.2 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Want to know why biotech investors can name genetech (S. San Fransisco, CA, USA : NYSE, DNA) in their sleep as the industry's most valuable player. Easy, according to samuel isaly, manager of the eaton vane worldwide health sciences find, only 40 of 1,000 biotech companies in biotech's history have ever attained profitability. Of those 40, only two genetech and amgen (thousand oaks, CA, USA, Nasdaq, AMGN) have remained independent and reached the sales and market value heights of the top pharmaceutical makers.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali